Tereza Lanitis

872 total citations
32 papers, 639 citations indexed

About

Tereza Lanitis is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Epidemiology. According to data from OpenAlex, Tereza Lanitis has authored 32 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 15 papers in Economics and Econometrics and 7 papers in Epidemiology. Recurrent topics in Tereza Lanitis's work include Atrial Fibrillation Management and Outcomes (17 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Cardiac Arrhythmias and Treatments (6 papers). Tereza Lanitis is often cited by papers focused on Atrial Fibrillation Management and Outcomes (17 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Cardiac Arrhythmias and Treatments (6 papers). Tereza Lanitis collaborates with scholars based in United States, United Kingdom and Germany. Tereza Lanitis's co-authors include Thitima Kongnakorn, David Neasham, Kevin Marsh, J. Jaime, Andreas Kuznik, Hemant Phatak, Luis Hernández, Gregory Y.H. Lip, Dale Rublee and Paul Dorian and has published in prestigious journals such as Journal of Clinical Oncology, Stroke and European Heart Journal.

In The Last Decade

Tereza Lanitis

30 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tereza Lanitis United States 14 331 324 103 77 57 32 639
Ingeborg Waernbaum Sweden 12 51 0.2× 114 0.4× 71 0.7× 125 1.6× 18 0.3× 36 933
David Warner United States 8 128 0.4× 110 0.3× 83 0.8× 3 0.0× 106 1.9× 24 459
Mehmet Akif Çakar Türkiye 11 30 0.1× 140 0.4× 23 0.2× 17 0.2× 84 1.5× 44 405
J Pons Spain 13 65 0.2× 111 0.3× 50 0.5× 7 0.1× 66 1.2× 24 421
Matthew Taylor United Kingdom 11 128 0.4× 55 0.2× 46 0.4× 3 0.0× 49 0.9× 37 373
Mike Drummond United Kingdom 14 400 1.2× 37 0.1× 81 0.8× 5 0.1× 230 4.0× 23 790
Derek A. Haas United States 14 82 0.2× 61 0.2× 52 0.5× 22 0.3× 76 1.3× 29 588
Eric Reyes United States 12 28 0.1× 355 1.1× 55 0.5× 17 0.2× 16 0.3× 20 626
Purna Mukhopadhyay United States 12 48 0.1× 163 0.5× 70 0.7× 41 0.5× 38 0.7× 27 679
Onur Başer Türkiye 11 91 0.3× 110 0.3× 40 0.4× 51 0.7× 29 0.5× 29 368

Countries citing papers authored by Tereza Lanitis

Since Specialization
Citations

This map shows the geographic impact of Tereza Lanitis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tereza Lanitis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tereza Lanitis more than expected).

Fields of papers citing papers by Tereza Lanitis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tereza Lanitis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tereza Lanitis. The network helps show where Tereza Lanitis may publish in the future.

Co-authorship network of co-authors of Tereza Lanitis

This figure shows the co-authorship network connecting the top 25 collaborators of Tereza Lanitis. A scholar is included among the top collaborators of Tereza Lanitis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tereza Lanitis. Tereza Lanitis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Andrade, Jason G., Richard Godin, Tereza Lanitis, et al.. (2022). Cost-effectiveness of atrial fibrillation screening in Canadian community practice. Heart Rhythm O2. 4(2). 103–110. 2 indexed citations
2.
Lanitis, Tereza, Irina Proskorovsky, Matthias Hünger, et al.. (2019). Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Advances in Therapy. 36(9). 2327–2341. 12 indexed citations
3.
Lanitis, Tereza, Xiaoyan Li, Gail Wygant, et al.. (2019). Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Applied Health Economics and Health Policy. 18(4). 533–545. 16 indexed citations
4.
Proskorovsky, Irina, Tereza Lanitis, Matthias Hünger, et al.. (2018). Projecting Overall Survival (OS) With Immuno-Oncology (IO) Treatments: Application of Alternative Approaches in Metastatic Merkel Cell Carcinoma (MMCC). Value in Health. 21. S6–S6. 1 indexed citations
5.
6.
Muszbek, N., Ananth Kadambi, Tereza Lanitis, et al.. (2016). The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma. Clinical Therapeutics. 38(3). 503–515. 9 indexed citations
7.
Lanitis, Tereza, et al.. (2016). Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Clinical Therapeutics. 38(3). 478–493.e16. 14 indexed citations
8.
Lip, Gregory Y.H., Tereza Lanitis, Thitima Kongnakorn, et al.. (2015). Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. Clinical Therapeutics. 37(11). 2476–2488.e27. 6 indexed citations
9.
Phatak, Hemant, et al.. (2015). Simulated Treatment Comparison of Time-To-Event (And Other Non-Linear) Outcomes. Value in Health. 18(7). A719–A719. 4 indexed citations
10.
11.
Kachroo, Sumesh, Hemant Phatak, Paul Dorian, et al.. (2014). Validation Of The Apixaban Cost-Effectiveness Model In Patients With Non-Valvular Atrial Fibrillation. Value in Health. 17(3). A113–A113. 1 indexed citations
12.
Lanitis, Tereza, et al.. (2014). Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism. Value in Health. 17(7). A488–A488. 4 indexed citations
13.
Kongnakorn, Thitima, Tereza Lanitis, Lieven Annemans, et al.. (2014). Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. Clinical Drug Investigation. 35(2). 109–119. 20 indexed citations
14.
Kongnakorn, Thitima, et al.. (2014). Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium. Clinical Drug Investigation. 34(10). 709–721. 14 indexed citations
15.
Lip, Gregory Y.H., Thitima Kongnakorn, Hemant Phatak, et al.. (2014). Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Clinical Therapeutics. 36(2). 192–210.e20. 73 indexed citations
16.
Marsh, Kevin, et al.. (2014). Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature. PharmacoEconomics. 32(4). 345–365. 191 indexed citations
17.
Dorian, Paul, Thitima Kongnakorn, Hemant Phatak, et al.. (2014). Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. European Heart Journal. 35(28). 1897–1906. 81 indexed citations
18.
Chapman, R., et al.. (2013). The Costs of Managing Genital Warts in the UK by Devolved Nation: England, Scotland, Wales and Northern Ireland. Value in Health. 16(7). A350–A350. 1 indexed citations
19.
20.
Carroll, Stuart, et al.. (2011). PIN35 Costs of Managing Genital Warts in the UK. Value in Health. 14(7). A271–A271. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingeborg Waernbaum Breakdown of academic impact, for papers by David Warner Breakdown of academic impact, for papers by Mehmet Akif Çakar Breakdown of academic impact, for papers by J Pons Breakdown of academic impact, for papers by Matthew Taylor Breakdown of academic impact, for papers by Mike Drummond Breakdown of academic impact, for papers by Derek A. Haas Breakdown of academic impact, for papers by Eric Reyes Breakdown of academic impact, for papers by Purna Mukhopadhyay Breakdown of academic impact, for papers by Onur Başer
Rankless by CCL
2026